Cogent Biosciences, Inc. (COGT)

14.13 +0.68 (+5.06%) At close: 04:00PM EDT

Cogent Biosciences, Inc.

200 Cambridge Park Drive
Suite 2500
Cambridge, MA 02140
United States
617 945 5576
https://www.cogentbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 77

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Andrew R. Robbins M.B.A.	Pres, CEO & Director	961.32k	N/A	1976
Dr. John Edward Robinson Ph.D.	Chief Scientific Officer	560.22k	N/A	N/A
Dr. Jessica Sachs M.D.	Chief Medical Officer	595.24k	N/A	1975
Mr. John L. Green C.A., CPA	CFO & Principal Accounting Officer	N/A	N/A	1980
Mr. Brad Barnett	Chief Technology Officer	N/A	N/A	N/A
Mr. Evan D. Kearns J.D.	Chief Legal Officer & Corp. Sec.	N/A	N/A	1980
Ms. Erin Schellhammer	Chief People Officer	N/A	N/A	N/A
Ms. Sara Saltzman	Sr. VP of Regulatory Affairs	N/A	N/A	N/A
Mr. Dana R. Martin Pharm.D.	Sr. VP of Medical Affairs & Chief Patient Officer	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Cogent Biosciences, Inc.’s ISS Governance QualityScore as of July 31, 2022 is 8. The pillar scores are Audit: 9; Board: 6; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.